Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Schroeder

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Molecular Cancer Therapeutics|March 31, 2021
<i>In Vivo</i> Efficacy of Tesevatinib in <i>EGFR</i>-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory SignalingSani H Kizilbash, Shiv K Gupta, Karen E Parrish, et al.
Molecular Cancer Therapeutics|October 7, 2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous SystemKaren E Parrish, Ling Cen, James Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Blood Advances|April 24, 2020
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host diseaseMark A Schroeder, H Jean Khoury, Madan Jagasia, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2013
Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenShivaprasad Manjappa, Pavan Kumar Bhamidipati, Keith E Stokerl-Goldstein, et al.
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Transplantation and Cellular Therapy|May 19, 2026
Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice GuidelinesZachariah DeFilipp, Amin Alousi, John E Levine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panelLin Yang, Michelle J Clarke, Brett L Carlson, et al.
Immunity|May 13, 2018
Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-toleranceJustin S A Perry, Emilie V Russler-Germain, You W Zhou, et al.
Blood|November 22, 2024
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationRamzi Abboud, Mark A Schroeder, Michael P Rettig, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Molecular Cancer Therapeutics|March 31, 2021
<i>In Vivo</i> Efficacy of Tesevatinib in <i>EGFR</i>-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory SignalingSani H Kizilbash, Shiv K Gupta, Karen E Parrish, et al.
Molecular Cancer Therapeutics|October 7, 2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous SystemKaren E Parrish, Ling Cen, James Murray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Blood Advances|April 24, 2020
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host diseaseMark A Schroeder, H Jean Khoury, Madan Jagasia, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2013
Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenShivaprasad Manjappa, Pavan Kumar Bhamidipati, Keith E Stokerl-Goldstein, et al.
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Transplantation and Cellular Therapy|May 19, 2026
Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice GuidelinesZachariah DeFilipp, Amin Alousi, John E Levine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panelLin Yang, Michelle J Clarke, Brett L Carlson, et al.
Immunity|May 13, 2018
Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-toleranceJustin S A Perry, Emilie V Russler-Germain, You W Zhou, et al.
Blood|November 22, 2024
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationRamzi Abboud, Mark A Schroeder, Michael P Rettig, et al.
Pageof 11